Dermatomyositis Drug Market
Global Dermatomyositis Drugs Market Size, Share & Trend Analysis Report by Type (Abatacept, Baricitinib, Dalazatide, Immune Globulin, and IMO-8400), by End-users (Hospitals, Clinics, and Others), Forecast (2022-2028)
The global dermatomyositis drugs market is anticipated to grow at considerable CAGR during the forecast year. Dermatomyositis is a rare inflammatory disease that causes muscle weakness and skin rashes. The skin rashes, and inflammation and swelling in the muscles are the symptoms of dermatomyositis. The drugs used for the treatment of these symptoms are called dermatomyositis drugs. One of the major factors driving the growth of the market is the increasing demand for dermatomyositis drugs due to the prevalence of dermatomyositis disease across the globe. According to a report published by National Org. for Rare Disease (NORD), dermatomyositis is a rare disease that can affect any age group i.e., from infant to 80 years. The most common age group affected by dermatomyositis is between 40 years and 60 years. There are around 9.63 cases per million people estimated to get affected by dermatomyositis. Around 3 in 1 million children are affected by juvenile dermatomyositis. These increasing cases of dermatomyositis are increasing the demand for dermatomyositis drugs propelling the growth of the global dermatomyositis drugs market.
Impact of COVID-19 on Global Dermatomyositis Drugs Market
COVID-19 has impacted the global economy due to a slowdown in the manufacturing of various industries. The market for dermatomyositis drugs is not affected during COVID-19, as it is a rare disease, and the distribution of the drugs was persistent due to pharmaceuticals being an essential commodity during COVID-19.
Segmental Outlook
The global dermatomyositis drugs market is segmented based on type and end-users. Based on type, the market is sub-segmented into abatacept, baricitinib, dalazatide, immune globulin, and IMO-8400. Based on end-users, the market is sub-segmented into hospitals, clinics, and others. Others include medical centers and pharmacies. Among these, the abatacept type of dermatomyositis drugs segment is expected to hold a prominent share in the global dermatomyositis drugs market due to increasing patients suffering from rheumatoid arthritis.
Global Dermatomyositis Drugs Market by End-users, 2021(%)
The Hospitals Segment is Anticipated to Hold a Major Share in the Global Dermatomyositis Drugs market.
The use of dermatomyositis drugs in the hospital segment is expected to hold a major share in the global dermatomyositis drugs market due to the increasing cases of dermatomyositis patients in the hospitals. Hospitals are the initial treatment center for most diseases. The rare diseases are mostly treated in hospitals for better efficacy. Thus, the increasing number of dermatomyositis disease patients in the hospitals is increasing the demand for dermatomyositis drugs in the hospitals for treatment resulting in the growth of the hospital’s segment among the global dermatomyositis drugs market.
Regional Outlooks
The global Dermatomyositis Drugs market is further segmented based on geography including North America (the US, and Canada), Europe (Italy, Spain, Germany, France, and Others), Asia-Pacific (India, China, Japan, South Korea, and Others), and the Rest of the World (the Middle East & Africa, and Latin America). The North American region is expected to hold the major share in the global dermatomyositis drugs market due to the presence of several key players in the region.
Global Dermatomyositis Drugs Market Growth by Region, 2022-2028
The Asia Pacific Region is Expected to Grow at a Significant CAGR among the Global Dermatomyositis Drugs Market During Forecast Year.
The Asia Pacific regional dermatomyositis drugs market is anticipated to grow at a significant CAGR during the forecast year due to the increasing number of patients suffering from dermatomyositis disease as the population of the region is very large. According to United Nations Population Funds (UNFPA), the population of the Asia Pacific region is 60% of the world’s total population with around 4.3 billion people in the region. The Asia Pacific region has some of the most populous countries including India and China. This large population of the Asia Pacific region is expected to see an increase in dermatomyositis disease patients. Thus, increasing the demand for dermatomyositis drugs. Resulting in the growth of the Asia Pacific region among the global dermatomyositis drugs market.
Market Players Outlook
The major companies serving the global Dermatomyositis Drugs market include AstraZeneca group Co., Eli Lilly and Co., F. Hoffmann-La Roche Ltd., Novartis International AG, Pfizer Inc., and many others. The market players are considerably contributing to the market growth by the adoption of various strategies including mergers & acquisitions, collaborations, fundings, and new product launches. For instance, in July 2021, the US Food and Drug Administration (FDA) approved a drug called Octagam 10%. The Octagam 10% is the immune globulin intravenous drug for the treatment of dermatomyositis disease in adults. The drug was developed by Octapharma USA for the treatment of dermatomyositis in adults.
The Report Covers
- Market value data analysis of 2021 and forecast to 2028.
- Annualized market revenues ($ million) for each market segment.
- Country-wise analysis of major geographical regions.
- Key companies operating in the global dermatomyositis drugs market. Based on the availability of data, information related to new product launches, and relevant news is also available in the report.
- Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
- Analysis of market entry and market expansion strategies.
- Competitive strategies by identifying ‘who-stands-where’ in the market
1.Report Summary
- Current Industry Analysis and Growth Potential Outlook
- Impact of COVID-19 on The Global Dermatomyositis Drugs Market
- Recovery Scenario of Global Dermatomyositis Drugs Market
1.1.Research Methods and Tools
1.2.Market Breakdown
1.2.1.By Segments
1.2.2.BY Region
2. Market Overview and Insights
2.1.Scope of the Report
2.2.Analyst Insight & Current Market Trends
2.2.1.Key Findings
2.2.2.Recommendations
2.2.3.Conclusion
3. Competitive Landscape
3.1.AstraZeneca group Co.
3.1.1.Overview
3.1.2.Financial Analysis
3.1.3.SWOT Analysis
3.1.4.Recent Developments
3.2.Eli Lilly and co.
3.2.1.Overview
3.2.2.Financial Analysis
3.2.3.SWOT Analysis
3.2.4.Recent Developments
3.3.F. Hoffmann-La Roche Ltd.
3.3.1.Overview
3.3.2.Financial Analysis
3.3.3.SWOT Analysis
3.3.4.Recent Developments
3.4.Novartis International AG
3.4.1.Overview
3.4.2.Financial Analysis
3.4.3.SWOT Analysis
3.4.4.Recent Developments
3.5.Pfizer Inc.
3.5.1.Overview
3.5.2.Financial Analysis
3.5.3.SWOT Analysis
3.5.4.Recent Developments
3.6.Key Strategy Analysis
3.7.Impact of Covid-19 on Key Players
4. Market Segmentation
4.1.Global Dermatomyositis Drugs Market by Type
4.1.1.Abatacept
4.1.2.Baricitinib
4.1.3.Dalazatide
4.1.4.Immune Globulin
4.1.5.IMO-8400
4.2.Global Dermatomyositis Drugs Market by End-users
4.2.1.Hospitals
4.2.2.Clinics
4.2.3.Others (Medical Center, and Pharmacies)
5. Regional Analysis
5.1.North America
5.1.1. The US
5.1.2.Canada
5.2.Europe
5.2.1.UK
5.2.2.Germany
5.2.3.Italy
5.2.4.Spain
5.2.5.France
5.2.6.Rest of Europe
5.3.Asia-Pacific
5.3.1.China
5.3.2.India
5.3.3.Japan
5.3.4.South Korea
5.3.5.Rest of Asia-Pacific
5.4.Rest of the World
6. Company Profiles
6.1.Abbott
6.2.Bristol Myers Squibb (BMS)
6.3.Corbus Pharmaceuticals, Inc.
6.4.GlaxoSmithKline plc
6.5.Idera Pharmaceuticals, Inc.
6.6.Merck Group
6.7.Neovacs
6.8.Octapharma AG
6.9.Takeda Pharmaceuticals Co. Ltd.
6.10.Viatris Inc.
1.GLOBAL DERMATOMYOSITIS DRUGS MARKET RESEARCH AND ANALYSIS BY TYPE, 2021-2028 ($ MILLION)
2.GLOBAL ABATACEPT DERMATOMYOSITIS DRUGS MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
3.GLOBAL BARICITINIB DERMATOMYOSITIS DRUGS MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
4.GLOBAL DALAZATIDE DERMATOMYOSITIS DRUGS MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
5.GLOBAL IMMUNE GLOBULIN DERMATOMYOSITIS DRUGS MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
6.GLOBAL IMO-8400 DERMATOMYOSITIS DRUGS MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
7.GLOBAL DERMATOMYOSITIS DRUGS MARKET RESEARCH AND ANALYSIS BY END-USERS, 2021-2028 ($ MILLION)
8.GLOBAL DERMATOMYOSITIS DRUGS IN HOSPITALS MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
9.GLOBAL DERMATOMYOSITIS DRUGS IN CLINICS MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
10.GLOBAL OTHERS DERMATOMYOSITIS DRUGS MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
11.GLOBAL DERMATOMYOSITIS DRUGS MARKET RESEARCH AND ANALYSIS BY GEOGRAPHY, 2021-2028 ($ MILLION)
12.NORTH AMERICAN DERMATOMYOSITIS DRUGS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
13.NORTH AMERICAN DERMATOMYOSITIS DRUGS MARKET RESEARCH AND ANALYSIS BY TYPE, 2021-2028 ($ MILLION)
14.NORTH AMERICAN DERMATOMYOSITIS DRUGS MARKET RESEARCH AND ANALYSIS BY END-USERS, 2021-2028 ($ MILLION)
15.EUROPEAN DERMATOMYOSITIS DRUGS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
16.EUROPEAN DERMATOMYOSITIS DRUGS MARKET RESEARCH AND ANALYSIS BY TYPE, 2021-2028 ($ MILLION)
17.EUROPEAN DERMATOMYOSITIS DRUGS MARKET RESEARCH AND ANALYSIS BY END-USERS, 2021-2028 ($ MILLION)
18.ASIA-PACIFIC DERMATOMYOSITIS DRUGS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
19.ASIA-PACIFIC DERMATOMYOSITIS DRUGS MARKET RESEARCH AND ANALYSIS BY TYPE, 2021-2028 ($ MILLION)
20.ASIA-PACIFIC DERMATOMYOSITIS DRUGS MARKET RESEARCH AND ANALYSIS BY END-USERS, 2021-2028 ($ MILLION)
21.REST OF THE WORLD DERMATOMYOSITIS DRUGS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
22.REST OF THE WORLD DERMATOMYOSITIS DRUGS MARKET RESEARCH AND ANALYSIS BY TYPE, 2021-2028 ($ MILLION)
23.REST OF THE WORLD DERMATOMYOSITIS DRUGS MARKET RESEARCH AND ANALYSIS BY END-USERS, 2021-2028 ($ MILLION)
1.IMPACT OF COVID-19 ON GLOBAL DERMATOMYOSITIS DRUGS MARKET, 2021-2028 ($ MILLION)
2.IMPACT OF COVID-19 ON GLOBAL DERMATOMYOSITIS DRUGS MARKET BY SEGMENT, 2021-2028 ($ MILLION)
3.RECOVERY OF GLOBAL DERMATOMYOSITIS DRUGS MARKET, 2021-2028 (%)
4.GLOBAL DERMATOMYOSITIS DRUGS MARKET SHARE BY TYPE, 2021 VS 2028 (%)
5.GLOBAL ABATACEPT DERMATOMYOSITIS DRUGS MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
6.GLOBAL BARICITINIB DERMATOMYOSITIS DRUGS MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
7.GLOBAL DALAZATIDE DERMATOMYOSITIS DRUGS MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
8.GLOBAL IMMUNE GLOBULIN DERMATOMYOSITIS DRUGS MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
9.GLOBAL IMO-8400 DERMATOMYOSITIS DRUGS MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
10.GLOBAL DERMATOMYOSITIS DRUGS MARKET SHARE BY END-USERS, 2021 VS 2028 (%)
11.GLOBAL DERMATOMYOSITIS DRUGS IN HOSPITALS MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
12.GLOBAL DERMATOMYOSITIS DRUGS IN CLINICS MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
13.GLOBAL DERMATOMYOSITIS DRUGS IN OTHER MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
14.GLOBAL DERMATOMYOSITIS DRUGS MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
15.US DERMATOMYOSITIS DRUGS MARKET SIZE, 2021-2028 ($ MILLION)
16.CANADA DERMATOMYOSITIS DRUGS MARKET SIZE, 2021-2028 ($ MILLION)
17.UK DERMATOMYOSITIS DRUGS MARKET SIZE, 2021-2028 ($ MILLION)
18.FRANCE DERMATOMYOSITIS DRUGS MARKET SIZE, 2021-2028 ($ MILLION)
19.GERMANY DERMATOMYOSITIS DRUGS MARKET SIZE, 2021-2028 ($ MILLION)
20.ITALY DERMATOMYOSITIS DRUGS MARKET SIZE, 2021-2028 ($ MILLION)
21.SPAIN DERMATOMYOSITIS DRUGS MARKET SIZE, 2021-2028 ($ MILLION)
22.REST OF EUROPE DERMATOMYOSITIS DRUGS MARKET SIZE, 2021-2028 ($ MILLION)
23.INDIA DERMATOMYOSITIS DRUGS MARKET SIZE, 2021-2028 ($ MILLION)
24.CHINA DERMATOMYOSITIS DRUGS MARKET SIZE, 2021-2028 ($ MILLION)
25.JAPAN DERMATOMYOSITIS DRUGS MARKET SIZE, 2021-2028 ($ MILLION)
26.SOUTH KOREA DERMATOMYOSITIS DRUGS MARKET SIZE, 2021-2028 ($ MILLION)
27.REST OF ASIA-PACIFIC DERMATOMYOSITIS DRUGS MARKET SIZE, 2021-2028 ($ MILLION)
28.REST OF THE WORLD DERMATOMYOSITIS DRUGS MARKET SIZE, 2021-2028 ($ MILLION)
